Turn Therapeutics Inc. announced November 4, 2025, the appointment of Andrew Scott as Vice President of Corporate Communications. Scott will oversee investor relations, capital markets strategy, and corporate communications for the clinical-stage biotechnology company.
In his new role, Scott will also support Turn Therapeutics' licensing and partnership initiatives. Bradley Burnam, Founder and Chief Executive Officer, stated, "We are thrilled to welcome Andrew to this newly created senior executive role. His addition comes as Turn Therapeutics enters a new phase of growth following its public listing and strengthened balance sheet. Andrew brings a wealth of experience that will help guide us as a public company, expand our investor engagement and ensure our story reaches the right audiences as we approach several important milestones in the coming year, including the completion of our Phase 2 clinical program."
Scott brings over 30 years of experience in capital markets and corporate finance. He previously served as a Managing Director of Investment Banking at ThinkEquity LLC and as Vice President of Business Development at Fortress Biosciences. Throughout his career, he has facilitated approximately $3 billion in fundraising across life-sciences transactions. He holds a BBA in Accounting from Pace University.
Turn Therapeutics, traded on Nasdaq under the ticker TTRX, is developing therapies for dermatology, wound care, and infectious disease. The company has secured three FDA clearances for its wound and dermatology formulations and is advancing late-stage clinical programs for eczema and onychomycosis. Turn is also involved in global health initiatives, focusing on thermostable vaccine delivery.
